Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Completed · Phase 3 · Has a placebo group

Conditions studied: Asthma

In brief

Primary Objective: To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab in improving participants-reported outcomes. * To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.

Key facts

Study ID: NCT02528214
Run by: Sanofi
People needed: 210
Starts: 2015-10-15
Expected to finish: 2017-11-13
Last updated by the study team: 2019-10-01

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult and adolescent (12 years of age or older) participants with a physician diagnosis of asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2014 guidelines and the following criteria:
Participants with severe asthma and a well-documented, regular prescribed treatment of maintenance corticosteroids in the 6 months prior to Visit 1 and using a stable OCS dose (ie, no change of OCS dose) for 4 weeks prior to Visit 1. Participants must be taking 5 to 35 mg/day of prednisone/prednisolone, or the equivalent, at Visit 1 and at the randomization visit. In addition, the participants must agree to switch to study-required prednisone/prednisolone as their OCS and use it per protocol for the duration of the study.
Existing treatment with high-dose inhaled corticosteroid (ICS; >500 mcg total daily dose of fluticasone propionate or equivalent) in combination with a second controller (ie, long-acting beta agonist [LABA], leukotriene receptor antagonist [LTRA]) for at least 3 months with a stable dose of ICS for >=1 month prior to Visit 1. In addition, participants requiring a third controller for their asthma are considered eligible for this study, and it should also be used for at least 3 months with a stable dose >= 1 month prior to Visit 1.
A forced expiratory volume in 1 second (FEV1) <80% of predicted normal for adults and <=90% of predicted normal for adolescents at Visit 1.
Evidence of asthma as documented by either: reversibility of at least 12% and 200 mL in FEV1 after the administration of 200 to 400 mcg (2 to 4 inhalations of albuterol/salbutamol or levalbuterol/levosalbutamol, or of a nebulized solution of albuterol/salbutamol or levalbuterol/levosalbutamol, if considered as a standard office practice) before randomization or documented in the 12 months prior to Visit 1 OR airway hyperresponsiveness (methacholine: provocative concentration that causes a positive reaction [PC20] of <8 mg/mL) documented in the 12 months prior to Visit 1.

You may not qualify if…

Participants <12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (for those countries where local regulations permit enrollment of adults only, participant recruitment will be restricted to those who were >=18 years of age).
Participants who weighed <30.0 kg.
Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss Syndrome, allergic bronchopulmonary aspergillosis, cystic fibrosis) which may impair lung function.
Clinical evidence or imaging (eg, chest X-ray, computed tomography, magnetic resonance imaging) within 12 months of Visit 1 with clinically significant findings of lung disease(s) other than asthma, as per local standard of care.
A participant who experiences a deterioration of asthma that results in emergency treatment or hospitalization within 4 weeks of Screening Visit 1.
A participant who requires 12 puffs or more of rescue medication on any 1 day in the week prior to Visit 1.
A participant who has experienced an upper or lower respiratory tract infection within the 4 weeks prior to screening.
Current smoker or cessation of smoking within 6 months prior to Visit 1.
Previous smoker with a smoking history >10 pack-years.
Comorbid disease that might interfere with the evaluation of the investigational medicinal product.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

Investigational Site Number 840014 — Rolling Hills Estates, California, United States
Investigational Site Number 840002 — St Louis, Missouri, United States
Investigational Site Number 840010 — Pittsburgh, Pennsylvania, United States
Investigational Site Number 840062 — Amarillo, Texas, United States
Investigational Site Number 840070 — McKinney, Texas, United States
Investigational Site Number 840128 — McKinney, Texas, United States
Investigational Site Number 840118 — Plano, Texas, United States
Investigational Site Number 032003 — Buenos Aires, Argentina
Investigational Site Number 032001 — Caba, Argentina
Investigational Site Number 032091 — Caba, Argentina
Investigational Site Number 056002 — Brussels, Belgium
Investigational Site Number 056003 — Ghent, Belgium
Investigational Site Number 056001 — Leuven, Belgium
Investigational Site Number 076013 — São Bernardo do Campo, Brazil
Investigational Site Number 076011 — São Paulo, Brazil
Investigational Site Number 076002 — Sorocaba, Brazil
Investigational Site Number 124009 — Calgary, Canada
Investigational Site Number 124016 — Hamilton, Canada
Investigational Site Number 124003 — Mississauga, Canada
Investigational Site Number 124013 — Ottawa, Canada
Investigational Site Number 124002 — Toronto, Canada
Investigational Site Number 124017 — Vancouver, Canada
Investigational Site Number 152007 — Quillota, Chile
Investigational Site Number 152005 — Santiago, Chile
Investigational Site Number 840022 — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.